Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of EA8001 in schizophrenia with inadequate response to at least two antipsychotics
jRCT2031250620Phase 3Recruiting
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evenamide in schizophrenia (3 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Change from baseline in PANSS total score at Week 12. Started Mar 2026; status: recruiting.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2031250620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250620.